title: Recombinant alpha interferon in metastatic renal cell carcinoma. A cooperative phase II study.
abstract: A total of 61 evaluable patients with advanced renal cell carcinoma have been treated with 3 x 10(6) IU per square meter of body surface with recombinant alpha 2b interferon three times a week within a Cooperative Phase II Study. Toxic death for terminal renal failure occurred in 1 patient (1.63%), and toxicities greater than WHO grade 2 were present in 10 cases (16%). The overall response rate after six months of treatment was 13.1% (partial response 4, minor response 4). Two complete responses were obtained at nine and fifteen months (3.3%). Long-lasting stabilization of disease was 13.1 percent.
authors.affiliation: Regional Hospital, Varese, Italy.
authors.forename: A V
authors.initials: AV
authors.lastname: Bono
authors.forename: L
authors.initials: L
authors.lastname: Reali
authors.forename: C
authors.initials: C
authors.lastname: Benvenuti
authors.forename: P
authors.initials: P
authors.lastname: Rigatti
authors.forename: A
authors.initials: A
authors.lastname: Gibba
authors.forename: S
authors.initials: S
authors.lastname: Cosciani-Cunico
authors.forename: M
authors.initials: M
authors.lastname: Brausi
authors.forename: D
authors.initials: D
authors.lastname: Vicini
authors.forename: M
authors.initials: M
authors.lastname: Pavone-Macaluso
authors.forename: G
authors.initials: G
authors.lastname: Anselmo
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins